Iteos Therapeutics Inc

Iteos Therapeutics — ESMO 2024

20 slides from Iteos Therapeutics's conference presentation, Sep 16, 2024

  1. Slide 1: GALAXIES Lung-201 Update ESMO 2024

    Cancer Immunotherapies by design™ GALAXIES Lung-201 Update ESMO 2024

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possib

  3. Slide 3: Introduction

    Introduction Michel Detheux, PhD Chief Executive Officer & President

  4. Slide 4: Next Steps

    Next Steps GALAXIES Lung-201: Longer-term follow-up data in 2025 GALAXIES Lung-301: Enrolling GALAXIES Lung-201Follow-up Interim Analysis Study Scope Population: Unresectable locally advanced/metastatic PD-L1 high 1L NSCLC Primary Endpoint: ORR1 per RECIST 1.1 by investigator assessment Follow-Up In

  5. Slide 5: Belrestotug: Designed to Enhance the Anti-Tumor Response through Activation of Multiple Immune Cells

    Belrestotug: Designed to Enhance the Anti-Tumor Response through Activation of Multiple Immune Cells NK Cell Cancer Cell Belrestotug FCg R T Cell CD112 CD155 CD112 CD155 TIGIT CD226 TIGIT CD226 DC NK cell MACROPHAGE FCg R FCg R Treg and exhausted T cells TIGIThigh 1 Binding to TIGIT Optimized affini

  6. Slide 6: Belrestotug: The First And Only TIGIT to Demonstrate Robust Target Engagement

    Belrestotug: The First And Only TIGIT to Demonstrate Robust Target Engagement iTeos AACR 2021 doi: 10.1136/jitc-2022-SITC2022.0768 doi: 10.1038/s41586-024-07121-9 *Merck vibostolimab has yet to publicly show Treg depletion data; Arcus’ domvanalimab is an Fc silent TIGIT and not capable of Treg deple

  7. Slide 7: GALAXIES Lung-201 Follow-Up Interim Analysis

    GALAXIES Lung-201 Follow-Up Interim Analysis David Feltquate, MD Chief Medical Officer

  8. Slide 8: GALAXIES Lung-201 - Phase 2 in 1L NSCLC

    GALAXIES Lung-201 - Phase 2 in 1L NSCLC Status Enrolling Masking Open label PDL1 Expression ≥50% Lines of Therapy No prior systemic therapy Delivery IV Infusion Study Design Objectives Evaluate belrestotug + dostarlimab safety, efficacy, PK/PD Primary Endpoint ORR Secondary Endpoint PFS, OS, DOR Cli

  9. Slide 9: Baseline Characteristics Were Balanced Across Arms

    Characteristic, n (%) Dostarlimab N=32 A: Belrestotug 100 mg + dostarlimab N=30 B: Belrestotug 400 mg + dostarlimab N=32 C: Belrestotug 1000 mg + dostarlimab N=30 Male 26 (81%) 18 (60%) 26 (81%) 16 (53%) Years of age, median (range) 69.0 (37–86) 68.5 (45–79) 67.0 (50–78) 68.0 (47–83) Race White 24 (

  10. Slide 10: Clinically Meaningful ORR Observed at Every Dose vs Dostarlimab Monotherapy

    Response measure in mITT Dostarlimab N=32 A: Belrestotug 100 mg + dostarlimab N=30 B: Belrestotug 400 mg + dostarlimab N=32 C: Belrestotug 1000 mg + dostarlimab N=30 Median follow-up, months (range)1 7.0 (0.2–16.6) 8.5 (0.3–14.3) 8.5 (0.4–16.2) 6.7 (2.4–9.7) ORR,2,3 % n (95% CI) 37.5% n=12 (21.1–56.

  11. Slide 11: Belrestotug + Dostarlimab Consistently Increased Depth of Response vs Dostarlimab Monotherapy

    Belrestotug + Dostarlimab Consistently Increased Depth of Response vs Dostarlimab Monotherapy Best Observed Response (Without Confirmation): PR SD PD 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 Maximum percentage change from baseline1 2 1 3 4 5 6 7 8 9 10 11 12 13 14 15

  12. Slide 12: Consistent Deep Tumor Reduction with Ongoing Responses

    Consistent Deep Tumor Reduction with Ongoing Responses by Belrestotug + Dostarlimab vs Dostarlimab Monotherapy Ongoing – in follow-up Died Ongoing – on study treatment Withdrawn 1Investigator assessed percentage change from baseline per RECIST 1.1 by investigator assessment. RECIST, Response Evaluat

  13. Slide 13: Numerically Greater Reduction of ctDNA with Belrestotug 400mg and 1000mg Cohorts

    Numerically Greater Reduction of ctDNA Associated with Belrestotug 400mg and 1000mg + Dostarlimab Cohorts 1000 700 500 300 200 100 0 -50 -80 -90 -95 -98 -100 ctDNA % change at Week 71 Dostarlimab (N=19) A: Belrestotug 100 mg + dostarlimab (N=18) B: Belrestotug 400 mg + dostarlimab (N=22) C: Belresto

  14. Slide 14: Belrestotug + Dostarlimab Broadly Consistent with Known Safety Profile

    Belrestotug + Dostarlimab Is Broadly Consistent with Known Safety Profile of Checkpoint Inhibitor Combinations Increase in immune-related adverse events with belrestotug + dostarlimab vs dostarlimab Event, n (%) Dostarlimab (N=32) A: Belrestotug 100 mg + dostarlimab (N=30) B: Belrestotug 400 mg + do

  15. Slide 15: Belrestotug + Dostarlimab Safety Profile: Most Common TR-irAE

    Belrestotug + Dostarlimab Is Broadly Consistent with Known Safety Profile of Checkpoint Inhibitor Combinations Most common TR-irAE were skin and subcutaneous tissue disorders The majority of Grade 2+ irAEs were skin and subcutaneous tissue disorders across all combination cohorts and were considered

  16. Slide 16: Closing Remarks

    Closing Remarks Michel Detheux, PhD Chief Executive Officer & President

  17. Slide 17: GALAXIES Lung-301 - Phase 3 in 1L NSCLC

    GALAXIES Lung-301 - Phase 3 in 1L NSCLC Status Enrolling Masking Double-blind PDL1 Expression ≥50% Lines of Therapy No prior systemic therapy Delivery IV Infusion Study Design Objectives Evaluate belrestotug + dostarlimab safety, efficacy vs placebo + pembrolizumab Primary Endpoint PFS, OS Secondary

  18. Slide 18: Deep Responses with Generally Manageable Safety Profile Observed

    Deep Responses with Generally Manageable Safety Profile Observed with Belrestotug + Dostarlimab ~60% cORR at every dose of belrestotug + dostarlimab vs ~28% for dostarlimab Generally Manageable IRAEs Belrestotug + dostarlimab safety profile broadly consistent with IO combinations Numerically Greater

  19. Slide 19: Upcoming TIGIT 2024 + 2025 Catalyst Calendar

    Upcoming TIGIT 2024 + 2025 Catalyst Calendar *Pro forma cash, cash equivalents and short-term investments NSCLC, non-small cell lung cancer; HNSCC, head and neck squamous cell carcinoma; ENT1, Equilibrative Nucleoside Transporter 1; MoA, Mechanism of Action ~$714M As of June 30, 2024 Runway through

  20. Slide 20: Cancer Immunotherapies by design

    Cancer Immunotherapies by design™ Nasdaq: ITOS September 2024

iTeos Therapeutics — ESMO 2024 on 6ix